

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAPLUS patent kind codes will be updated
NEWS	25	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	26	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	27	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	28	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:06:48 ON 14 DEC 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:07:10 ON 14 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

DICTIONARY FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10568380.str



chain nodes :

12 13 14 15 16 17 18 19 20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

2-10 4-16 5-12 12-13 12-19 13-14 13-15 14-20 16-17 16-18

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

5-12 12-13 13-14 13-15 16-17 16-18

exact bonds :

1-2 1-5 2-3 2-10 3-4 4-5 4-16 12-19 14-20

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS


19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 15:07:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 467 TO 1253

PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> S L1 SSS FULL

FULL SEARCH INITIATED 15:07:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS



SEARCH TIME: 00.00.01

550 ANSWERS

L3 550 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10568380a.str



chain nodes :

12 13 14 15 16 17 18 19 20 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

2-10 4-16 5-12 12-13 12-19 13-14 13-15 14-20 16-17 16-18

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

5-12 12-13 13-14 13-15 16-17 16-18

exact bonds :

1-2 1-5 2-3 2-10 3-4 4-5 4-16 12-19 14-20

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 : 6 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
 19:CLASS 20:CLASS 22:CLASS 23:Atom

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 15:09:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 467 TO 1253

PROJECTED ANSWERS: 56 TO 504

L5 14 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 15:09:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS

SEARCH TIME: 00.00.01

271 ANSWERS

L6 271 SEA SSS FUL L4

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

335.20

335.41

FILE 'HCAPLUS' ENTERED AT 15:10:08 ON 14 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 13 Dec 2006 (20061213/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:06:48 ON 14 DEC 2006)

FILE 'REGISTRY' ENTERED AT 15:07:10 ON 14 DEC 2006

L1 STRUCTURE UPLOADED
L2 22 S L1
L3 550 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 14 S L4
L6 271 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:10:08 ON 14 DEC 2006

=> s l3

L7 17 L3

=> s l6

L8 7 L6

=> s l7 and p/dt

5534189 P/DT

L9 13 L7 AND P/DT

=> s l9 and us/pc

1616988 US/PC

L10 6 L9 AND US/PC

=> d l8 ibib abs hitstr tot

L8 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:469629 HCAPLUS

DOCUMENT NUMBER: 144:488936
 TITLE: Preparation of amino acid aryl or heteroaryl derivatives as glycogen phosphorylase inhibitors
 INVENTOR(S): Evans, Karen; Cichy-Knight, Maria; Coppo, Frank Teen; Dwornik, Kate Ann; Gale, Jennifer Paul; Garrido, Dulce Maria; Li, Yue Hu; Patel, Mehul P.; Tavares, Francis X.; Thomson, Stephen Andrew; Dickerson, Scott Howard; Peat, Andrew James; Sparks, Steven Meagher; Banker, Pierette; Cooper, Joel P.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int: Appl., 681 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006052722	A1	20060518	WO 2005-US39956	20051104
W: AE, AG, AL, AM, <u>AT, AU, AZ</u> , BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-626389P P 20041109

OTHER SOURCE(S): MARPAT 144:488936

AB The invention relates to compds. R-Ar-NR₁CO-X-Ar' [R is CO₂H or carbamoyl which may be substituted by alkyl, aryl, carboxyalkyl, etc.; Ar is an aromatic, heteroarom., cycloaliph. or heterocyclic ring which may fused to an aromatic or heteroarom. ring; X is carbon, nitrogen, oxygen or sulfur; Ar' is an aromatic or heteroarom. ring; R₁ is H or alkyl] or their pharmaceutically-acceptable salts, which are inhibitors of glycogen phosphorylase and can be used to treat diabetes, conditions associated with diabetes, or tissue ischemia, including myocardial ischemia. Thus, N-[3-[[[(2,6-dimethylphenyl)amino]carbonyl]amino]-2-naphthoyl]-L-aspartic acid was prepared by treating L-Asp(tBu)-Wang Resin with 3-amino-2-naphthalenecarboxylic acid and then 2,6-dimethylphenyl isocyanate. The product showed IC₅₀ = 0.46 μ M for inhibition of glycogen phosphorylase.

IT 887241-34-1P 887241-42-1P 887241-44-3P
 887241-46-5P 887241-48-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid aryl or heteroaryl derivs. as glycogen phosphorylase inhibitors)

RN 887241-34-1 HCAPLUS

CN Cyclohexaneacetic acid, α -[[[2-[[[(2,6-dichlorophenyl)amino]carbonyl]amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl]amino]-, (α S)-(9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 887241-42-1 HCAPLUS

CN Cyclohexaneacetic acid, α-[[[5-(4-methoxyphenyl)-2-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]-3-thienyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887241-44-3 HCAPLUS

CN Cyclohexaneacetic acid, α-[[[2-[[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887241-46-5 HCAPLUS

CN Cyclohexaneacetic acid, α -[[[2-[[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]carbonyl]amino]-, (α S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 887241-48-7 HCAPLUS


CN Cyclohexaneacetic acid, α -[[[5-[4-(trifluoromethoxy)phenyl]-2-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]-3-thienyl]carbonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 887247-43-0P 887247-52-1P 887249-64-1P
 887249-67-4P 887249-69-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino acid aryl or heteroaryl derivs. as glycogen
 phosphorylase inhibitors)
 RN 887247-43-0 HCAPLUS
 CN Cyclohexaneacetic acid, α -[[[2-[[[(2,6-dichlorophenyl)amino]carbonyl
]amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl]amino]-, methyl ester,
 (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 887247-52-1 HCAPLUS
 CN Cyclohexaneacetic acid, α -[[[5-(4-methoxyphenyl)-2-[[[(2,4,6-
 trimethylphenyl)amino]carbonyl]amino]-3-thienyl]carbonyl]amino]-, methyl
 ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887249-64-1 HCAPLUS

CN Cyclohexaneacetic acid, α -[[[2-[[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887249-67-4 HCAPLUS

CN Cyclohexaneacetic acid, α -[[[2-[[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-5-[4-(trifluoromethoxy)phenyl]-3-thienyl]carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887249-69-6 HCAPLUS

CN Cyclohexaneacetic acid, α -[[[5-[4-(trifluoromethoxy)phenyl]-2-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]-3-thienyl]carbonyl]amino]-, methyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:638873 HCAPLUS

DOCUMENT NUMBER: 143:153276



TITLE: Preparation of substituted heterocycles, particularly ureidothiophenes, as CHK1 kinase inhibitors for treating neoplasm

INVENTOR(S): Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janotka, James; Lyne, Paul; Su, Mei; Toader, Dorin; Yu, Dingwei; Yu, Yan

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066163	A2	20050721	WO 2004-GB5400	20041224
WO 2005066163	A3	20050901		
W: AE, AG, AL, AM, AT , AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312193	A1	20050721	AU 2004-312193	20041224
CA 2552050	AA	20050721	CA 2004-2552050	20041224
NO 2006003449	A	20060727	NO 2006-3449	20060726
PRIORITY APPLN. INFO.:			US 2004-534310P	P 20040105
			US 2004-553305P	P 20040315
			WO 2004-GB5400	W 20041224

OTHER SOURCE(S): MARPAT 143:153276
 GI




AB Title compds. I [wherein X = NH, S, O; Y = CH, N; R1 = CN, (un)substituted alk(en)yl, alkoxy, aryl, etc.; R2, R3 = independently CONH2 and derivs., SO2NH2 and derivs., NHCONHR4; R4 = H, OH, benzyl, etc.; and their pharmaceutically acceptable salts; provided that when X = S; Y = CH; R2 = CONH2 and derivs.; and R3 = NHCONHR4; then R1 cannot be hydroxyphenyl or

alkoxyphenyl; with the exception of certain compds.] were prepared as checkpoint kinase 1 inhibitors for treating cancer. For example, a 7-step synthesis of ureidothiophene salt II•HCl, starting from phenylacetaldehyde and cyanomethyl acetate, is given. I had IC50 or EC50 ≤ 100 μM in one or both, checkpoint kinase 1 and abrogation assays.


IT 860352-21-2P 860352-39-2P 860352-58-5P
 860352-70-1P, 5-(3-Fluoro-4-methoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide 860352-74-5P
 860352-76-7P, 5-(2,4-Dimethoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide 860352-80-3P
 860352-81-4P 860352-82-5P, 5-(5-Chloro-2-methoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide
 860352-83-6P, 5-(2,5-Dimethoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide 860352-85-8P,
 5-(5-Fluoro-2-methoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide 860352-87-0P 860352-88-1P
 860352-89-2P 860353-71-5P, 5-(3,4-Dimethoxyphenyl)-2-ureidothiophene-3-carboxylic acid N-(piperidin-4-yl)amide
 860353-75-9P, 5-(3,4-Dimethoxyphenyl)-2-ureidothiophene-3-carboxylic acid (S)-azepan-3-ylamide 860353-87-3P,
 5-(3,4-Dihydroxyphenyl)-2-ureidothiophene-3-carboxylic acid N-(piperidin-4-yl)amide 860353-88-4P, 4-[[[5-(3,4-Dimethoxyphenyl)-2-ureidothien-3-yl]carbonyl]amino]piperidine-1-carboxylic acid tert-butyl ester
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of ureidothiophenes as CHK1 kinase inhibitors for treating neoplasm)
 RN 860352-21-2 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dimethoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860352-39-2 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluoro-2-hydroxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-58-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-dimethoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-70-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluoro-4-methoxyphenyl)-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860352-74-5 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-fluoro-4-(phenylmethoxy)phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860352-76-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-dimethoxyphenyl)-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860352-80-3 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-difluoro-4-methoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-81-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-fluoro-4-(phenylmethoxy)phenyl]-N-(3S)-3-piperidinyloxy (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-82-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(5-chloro-2-methoxyphenyl)-N-[(3S)-hexahydro-1H-azepin-3-yl]oxy (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860352-83-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,5-dimethoxyphenyl)-N-
[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860352-85-8 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(5-fluoro-2-methoxyphenyl)-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860352-87-0 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(3S)-3-piperidinyl-5-(2,3,4-trimethoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-88-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(5-chloro-2-methoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 860352-89-2 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-fluoro-2-(phenylmethoxy)phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 860353-71-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dimethoxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 860353-75-9 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dimethoxyphenyl)-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 860353-87-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dihydroxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 860353-88-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(aminocarbonyl)amino]-5-(3,4-dimethoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:158658 HCAPLUS

DOCUMENT NUMBER: 142:261391

TITLE:

INVENTOR(S):

Preparation of thiophene compounds as CHK1 inhibitors
Ashwell, Susan; Gero, Thomas; Ioannidis, Stophanos;
Janetka, James; Lyne, Paul; Oza, Vibha; Springer,
Stephanie; Su, Mei; Yu, Dingwei

PATENT ASSIGNEE(S):

SOURCE:

Astrazeneca AB, Swed.; Astrazeneca UK Limited
PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:



Patent

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016909	A1	20050224	WO 2004-GB3473	20040812
W: AE, AG, AL, AM, AT , AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004265140	A1	20050224	AU 2004-265140	20040812
CA 2535652	AA	20050224	CA 2004-2535652	20040812
EP 1660474	A1	20060531	EP 2004-768043	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004013585	A	20061017	BR 2004-13585	20040812
CN 1867557	A	20061122	CN 2004-80030364	20040812
NO 2006000718	A	20060301	NO 2006-718	20060214
PRIORITY APPLN. INFO.:			US 2003-495580P	P 20030815
			US 2004-576416P	P 20040528
			WO 2004-GB3473	W 20040812
OTHER SOURCE(S):		MARPAT 142:261391		
GI				




AB Title compds. I [R1, R2 = H, (un)substituted alkyl, (un)substituted heterocyclyl; with proviso that R1 and R2 are not both H; or R1 and R2 and the N to which they are attached in combination form an optionally substituted heterocyclyl; R4 = H, OH, (un)substituted carbocyclyl, etc.; R5 = H, (un)substituted carbocyclyl, (un)substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, amidation of compound II with (CH₃)₂Al-3-BOC-(S)-3-aminopiperidine, e.g., in-situ prepared by reaction of (S)-3-aminopiperidine-1-carboxylic acid tert-Bu ester with (CH₃)₃Al, followed by acidic deprotection afforded compound I [NR1R2 = (S)-piperidin-3-ylamino; R4 = H; OR5 = 4-MeO]·HCl in 57% overall yield. In CHK 1 (checkpoint kinase 1) inhibition assays, the IC₅₀ value of compound I [NR1R2 = piperidin-3-ylamino; R4 = H; OR5 = 4-Et₂NCH₂CH₂O]·CF₃CO₂H was 10 nM. Compds. I are claimed useful for the treatment of cancer, infection.

IT 845888-64-4
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (preparation of thiophene compds. as CHK1 inhibitors for treatment of cancer, infection)

RN 845888-64-4 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 845887-64-1P 845887-66-3P 845887-68-5P
 845887-69-6P 845887-71-0P 845887-72-1P
 845887-73-2P 845887-77-6P 845887-79-8P
 845887-80-1P 845887-82-3P 845887-84-5P
 845887-85-6P 845887-86-7P 845887-88-9P
 845887-90-3P 845887-92-5P 845887-93-6P
 845887-95-8P 845887-96-9P 845887-97-0P
 845887-98-1P 845887-99-2P 845888-00-8P
 845888-01-9P 845888-02-0P 845888-03-1P
 845888-04-2P 845888-05-3P 845888-06-4P
 845888-07-5P 845888-08-6P 845888-09-7P
 845888-10-0P 845888-11-1P 845888-12-2P
 845888-13-3P 845888-14-4P 845888-15-5P
 845888-16-6P 845888-17-7P 845888-18-8P
 845888-19-9P 845888-20-2P 845888-21-3P
 845888-22-4P 845888-23-5P 845888-24-6P
 845888-25-7P 845888-26-8P 845888-27-9P
 845888-28-0P 845888-29-1P 845888-30-4P
 845888-31-5P 845888-32-6P 845888-33-7P
 845888-34-8P 845888-35-9P 845888-36-0P
 845888-37-1P 845888-38-2P 845888-40-6P

845888-41-7P 845888-42-8P 845888-43-9P
 845888-46-2P 845888-47-3P 845888-48-4P
 845888-49-5P 845888-50-8P 845888-51-9P
 845888-52-0P 845888-53-1P 845888-55-3P
 845888-56-4P 845888-57-5P 845888-58-6P
 845888-59-7P 845888-61-1P 845888-63-3P
 845888-65-5P 845888-66-6P 845888-68-8P
 845888-70-2P 845888-71-3P 845888-72-4P
 845888-73-5P 845888-74-6P 845888-75-7P
 845888-76-8P 845888-77-9P 845888-78-0P
 845888-80-4P 845888-81-5P 845888-82-6P
 845888-85-9P 845888-86-0P 845888-87-1P
 845888-88-2P 845888-89-3P 845888-90-6P
 845888-91-7P 845888-92-8P 845888-93-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thiophene compds. as CHK1 inhibitors for treatment of
 cancer, infection)


RN 845887-64-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-
 (diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl
 ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-63-0


CMF C28 H41 N5 O5 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 845887-66-3 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 845887-65-2
 CMF C23 H33 N5 O3 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 845887-68-5 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-67-4
 CMF C23 H33 N5 O3 S


10568380.trn



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 845887-69-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845887-71-0 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-70-9

CMF C28 H41 N5 O5 S


10568380.trn



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 845887-72-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-4-piperidinyloxy (9CI) (CA INDEX NAME)



RN 845887-73-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3R)-hexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845887-77-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-[3-(hydroxymethyl)phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-76-5


CMF C25 H30 N4 O4 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 845887-79-8 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-4-piperidiny]-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)


CM 1

CRN 845887-78-7
 CMF C23 H33 N5 O3 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 845887-80-1 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845887-82-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-4-piperidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-81-2


CMF C18 H22 N4 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 845887-84-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-pyridinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-83-4

10568380.trn


CMF C23 H27 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 845887-85-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 845887-86-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-hexahydro-1-methyl-1H-azepin-3-yl]-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845887-88-9 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-[3-(hydroxymethyl)phenyl]-; mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 845887-87-8
 CMF C25 H30 N4 O4 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 845887-90-3 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-pyrrolidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 845887-89-0
 CMF C22 H31 N5 O3 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 845887-92-5 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-pyridinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845887-91-4
 CMF C23 H27 N5 O3 S


10568380.trn



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 845887-93-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-1-methyl-3-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 845887-95-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-pyrrolidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 845887-94-7
CMF C22 H31 N5 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 845887-96-9 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3R)-3-piperidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845887-97-0 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845887-98-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845887-99-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(dimethylamino)ethyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-00-8 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(diethylamino)ethyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-01-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-hexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-02-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3R)-3-piperidiny]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-03-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(4-

piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-04-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-3-pyrrolidinyl- (9CI) (CA INDEX NAME)



RN 845888-05-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(1-ethyl-3-piperidinyl)-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845888-06-4 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-1-ethylhexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845888-07-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 845888-08-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 845888-09-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 845888-10-0 HCAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845888-11-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 845888-12-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 845888-13-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845888-14-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-15-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 845888-16-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-3-azetidiny-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-17-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845888-18-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 845888-19-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-20-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-21-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-22-4 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-23-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(trans-4-hydroxycyclohexyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 845888-24-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 845888-25-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[1-[(3,5-dimethoxyphenyl)methyl]-4-piperidinyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

10568380.trn




RN 845888-26-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-27-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-28-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-29-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 845888-30-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 845888-31-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 845888-32-6 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845888-33-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-34-8 HCAPLUS

CN 1-Azetidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845888-35-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-36-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 845888-37-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-38-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-40-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-methoxyethyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845888-41-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-42-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-[(2-furanylmethyl)thio]ethyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845888-43-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 845888-46-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(1,2,3,4-tetrahydro-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 845888-47-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(1,3-benzodioxol-5-ylmethyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845888-48-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 845888-49-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845888-50-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 845888-51-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 845888-52-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(4-fluorophenyl)methyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 845888-53-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845888-55-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 845888-56-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 845888-57-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 845888-58-6 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 845888-59-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

10568380.trn



RN 845888-61-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-(3S)-3-piperidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845888-60-0

CMF C23 H33 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 845888-63-3 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-(3R)-3-piperidinyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845888-62-2

CMF C23 H33 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 845888-65-5 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845888-64-4

CMF C28 H41 N5 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 845888-66-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845888-68-8 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845888-67-7

CMF C28 H41 N5 O5 S


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 845888-70-2 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[[[(2,5-dimethoxyphenyl)amino]carbonyl]amino]-5-(4-methoxyphenyl)-N-3-piperidinyl- (9CI) (CA INDEX NAME)



RN 845888-71-3 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[4-[2-(diethylamino)ethoxy]phenyl]-2-[[[(pyrazinylamino)carbonyl]amino]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-72-4 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[3-[2-(diethylamino)ethoxy]phenyl]-2-[[pyrazinylamino)carbonyl]amino]-N-(3S)-3-pyrrolidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 845888-73-5 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[3-[2-(diethylamino)ethoxy]phenyl]-N-4-piperidinyl-2-[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 845888-74-6 HCAPLUS
 CN 3-Thiophenecarboxamide, N-[(3S)-hexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)-2-[[pyrazinylamino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 845888-75-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl-2-[[pyrazinylamino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 845888-76-8 HCAPLUS
 CN 3-Thiophenecarboxamide, N-(2-aminoethyl)-5-(4-methoxyphenyl)-2-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 845888-77-9 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl-2-[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 845888-78-0 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-4-piperidinyl-2-[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 845888-80-4 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[5-[3-[2-(diethylamino)ethoxy]phenyl]-2-[[pyrazinylamino)carbonyl]amino]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 845888-79-1

10568380.trn


CMF C32 H43 N7 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 845888-81-5 HCAPLUS


CN 3-Thiophenecarboxamide, 5-[4-[2-(diethylamino)ethoxy]phenyl]-N-4-piperidinyl-2-[[pyrazinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 845888-82-6 HCAPLUS


CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-2-[[pyrazinylamino)carbonyl]amino]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845888-85-9 HCAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[5-(4-methoxyphenyl)-2-
[[pyrazinylamino]carbonyl]amino]-3-thienyl]carbonyl]amino]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 845888-86-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[5-[4-[2-(diethylamino)ethoxy]phenyl]-2-
[[pyrazinylamino]carbonyl]amino]-3-thienyl]carbonyl]amino]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10568380.trn



RN 845888-87-1 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[4-[2-(diethylamino)ethoxy]phenyl]-2-
[[hydroxyamino]carbonylamino]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 845888-88-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-hexahydro-1H-
azepin-3-yl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-89-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-hydroxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-90-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-91-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(phenylmethoxy)phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-92-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 845888-93-9 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[4-[2-(diethylamino)ethoxy]phenyl]-2-[[[(hydroxyamino)carbonyl]amino]-N-(3S)-3-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 845887-63-0 845887-65-2 845887-67-4
 845887-70-9 845887-76-5 845887-78-7
 845887-83-4 845887-87-8 845887-89-0
 845887-91-4 845887-94-7 845888-60-0
 845888-62-2 845888-67-7 845888-79-1
 845888-94-0 845888-95-1 845888-96-2
 845888-97-3 845888-98-4 845888-99-5
 845889-01-2 845889-02-3 845889-03-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(preparation of thiophene compds. as CHK1 inhibitors for treatment of
 cancer, infection)


RN 845887-63-0 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845887-65-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 845887-67-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845887-70-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845887-76-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 845887-78-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 845887-83-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 845887-87-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-[3-(pyridin-3-yl)propyl]- (9CI) (CA INDEX NAME)




RN 845887-89-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 845887-91-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-3-pyrrolidinyl- (9CI) (CA INDEX NAME)



RN 845887-94-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-pyrrolidinyl- (9CI) (CA INDEX NAME)



RN 845888-60-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-62-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-67-7 HCAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845888-79-1 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[5-[3-[2-(diethylamino)ethoxy]phenyl]-2-[(pyrazinylamino)carbonyl]amino]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 845888-94-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-hexahydro-1-

10568380.trn

methyl-1H-azepin-3-yl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-95-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-[(3S)-1-methyl-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-96-2 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-hexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845888-97-3 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(1-ethyl-3-piperidiny)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 845888-98-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[(3S)-1-ethylhexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845888-99-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-01-2 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[3-[2-(diethylamino)ethoxy]phenyl]-2-[[pyrazinylamino)carbonyl]amino]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-02-3 HCAPLUS


CN 3-Thiophenecarboxamide, N-[(3S)-hexahydro-1H-azepin-3-yl]-5-(4-methoxyphenyl)-2-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845889-03-4 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[3-[2-(diethylamino)ethoxy]phenyl]-N-3-piperidinyl-2-[[pyrazinylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 845889-06-7P 845889-07-8P 845889-15-8P

845889-16-9P 845889-18-1P 845889-23-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiophene compds. as CHK1 inhibitors for treatment of cancer, infection)

RN 845889-06-7 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-07-8 HCAPLUS

CN 1H-Azepine-1-carboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-3-thienyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-15-8 HCAPLUS

CN 1H-Azepine-1-carboxylic acid, hexahydro-3-[[[5-(4-methoxyphenyl)-2-[[[pyrazinylamino]carbonyl]amino]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-16-9 HCAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[5-[4-[2-(diethylamino)ethoxy]phenyl]-2-[(hydroxyamino)carbonyl]amino]-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845889-18-1 HCAPLUS


CN 1H-Azepine-1-carboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845889-23-8 HCAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-3-thienyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:606461 HCAPLUS
 DOCUMENT NUMBER: 141:157026
 TITLE: Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
 INVENTOR(S): Morley, Andrew David; Poyser, Jeffrey Philip
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004063185	A1	20040729	WO 2004-GB106	20040113
WO 2004063185	C1	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203967	A1	20040729	AU 2004-203967	20040113
CA 2512336	AA	20040729	CA 2004-2512336	20040113
EP 1583756	A1	20051012	EP 2004-701632	20040113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006774	A	20051227	BR 2004-6774	20040113
CN 1738812	A	20060222	CN 2004-80002304	20040113
JP 2006515355	T2	20060525	JP 2006-500206	20040113
US 2006111431	A1	20060525	US 2005-542044	20050713
NO 2005003810	A	20051012	NO 2005-3810	20050812
PRIORITY APPLN. INFO.:			SE 2003-91	A 20030115
			WO 2004-GB106	A 20040113
OTHER SOURCE(S):		MARPAT 141:157026		
GI				



AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; X = C(R4R5)yNR3(CR4R5)m-Ar; y = n + 1; n = 1-3; m = 0-3; R3 = H, (un)substitued alkenyl, alkyl; R4, R5 = H, alkyl with provisos; Ar = Ph ring or a 5- or 6- membered heterocyclic ring containing one to three heteroatoms, e.g., O, N, S;] and their pharmaceutically acceptable salts were prepared. For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 1-bromo-2-[2-chloroethoxy]benzene and N-methylbenzylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 6-examples of compds. I exhibited IC50 values ranging from 0.01-1.43 μ M, e.g., the IC50 value of thiophenylcarboxamide III was 0.04 μ M. Compds. I are claimed useful for the treatment of inflammatory diseases.


IT 727741-81-3P 727741-82-4P 727741-83-5P,

2-[(Aminocarbonyl)amino]-5-[2-[2-(benzylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-84-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(benzyl-N-methylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-85-7P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(1,3-dihydro-2H-isindol-2-yl)ethoxy]phenyl]thiophene-3-carboxamide 727741-86-8P, 2-[(Aminocarbonyl)amino]-5-[2-[1-(4-fluorobenzyl)pyrrolidin-3-yl]oxy]phenyl]thiophene-3-carboxamide 727741-87-9P, 2-[(Aminocarbonyl)amino]-5-[2-(1-benzylpyrrolidin-3-yloxy)phenyl]thiophene-3-carboxamide 727741-88-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-fluorobenzyl)amino]ethoxy]phenyl]thiophene-3-carboxamide 727741-89-1P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-3-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-90-4P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-2-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-91-5P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-4-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)


RN 727741-81-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[(2-chlorophenyl)methyl]methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-82-4 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[(4-chlorophenyl)methyl]methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-83-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-
[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

RN 727741-84-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-
[methyl(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

RN 727741-85-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(1,3-dihydro-2H-
isoindol-2-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


RN 727741-86-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[1-[(4-
fluorophenyl)methyl]-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-87-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-88-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[[[4-fluorophenyl)methyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-89-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(methyl-3-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-90-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 727741-91-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(methyl-4-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 727741-95-9P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-benzylcarbamate
 727742-03-2P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-(4-fluorobenzyl)carbamate 727742-06-5P, tert-Butyl-N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-pyridin-3-ylmethylcarbamate 727742-09-8P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-


yl]phenoxy]ethyl]-N-(pyridin-2-ylmethyl)carbamate 727742-12-3P,
tert-Butyl-N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-
yl]phenoxy]ethyl]-N-pyridin-4-ylmethylcarbamate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment
of inflammatory diseases.)


RN 727741-95-9 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-
thienyl]phenoxy]ethyl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)




RN 727742-03-2 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-
thienyl]phenoxy]ethyl] [(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 727742-06-5 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-
thienyl]phenoxy]ethyl] (3-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 727742-09-8 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl](2-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 727742-12-3 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl](4-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:282559 HCAPLUS

DOCUMENT NUMBER: 138:304153

TITLE: Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders

INVENTOR(S): Parrish, Cynthia A.; Callahan, James F.; Li, Yue; Stavenger, Robert A.; Holt, Dennis A.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029241	A1	20030410	WO 2002-US31752	20021004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-326977P P 20011004

OTHER SOURCE(S): MARPAT 138:304153

GI



AB Ureidothiophenes (shown as I; variables defined below; e.g. 5-(4-fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 46 example preps. are included. For I: R1 = H, C1-2 alkyl, XH, XCH3, C1-2-alkyl-XH, C1-2 alkyl-XCH3, C(O)NH2, C(O)NHCH3, and C(O)-C1-2-alkyl; X = O, S, and NH; R2 = C(O)R5, CO2R5, C(O)NHR5, C(O)NHC(:NH)R5, C(O)NHC(:NH)NR5R6, C(O)NHC(O)R5, C(O)NHC(O)NR5R6, SO2R5, S(O)R5, SO3R5, and PO3R5R6. R3 is H or halogen; R4 is aryl or heteroaryl; addnl. details are given in the claims.

IT 354812-11-6P, 5-(4-Methoxyphenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-35-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-44-7P, 5-(3-Hydroxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-51-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-53-8P, 5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide

10568380.trn


507475-55-0P, 5-(3,4-Dimethoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-59-4P, 5-(3-Methoxyphenyl)-2-ureidothiophene-3-carboxylic acid amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)


RN 354812-11-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 507475-35-6 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-2-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 507475-44-7 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(3-hydroxyphenyl)-2-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 507475-51-6 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-2-[[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 507475-53-8 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(4-hydroxy-3-methoxyphenyl)-N-methyl-2-
[[(methylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)




RN 507475-55-0 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-2-
[[(methylamino)carbonyl]amino] - (9CI) (CA INDEX NAME)



RN 507475-59-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:97411 HCAPLUS

DOCUMENT NUMBER: 138:137162

TITLE: Preparation of ureido-carboxamido thiophenes as, inhibitors of IKK2 kinase

INVENTOR(S): Faull, Alan; Johnstone, Craig; Morley, Andrew; Poyser, Jeffrey Philip

PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.

SOURCE: PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2454703	AA	20030206	CA 2002-2454703	20020719
EP 1421074	A1	20040526	EP 2002-751935	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011473	A	20041026	BR 2002-11473	20020719
CN 1541214	A	20041027	CN 2002-815836	20020719
JP 2005503372	T2	20050203	JP 2003-515517	20020719
NZ 530750	A	20050826	NZ 2002-530750	20020719
US 2004242573	A1	20041202	US 2004-484569	20040122
US 7125896	B2	20061024		
ZA 2004000492	A	20050422	ZA 2004-492	20040122
NO 2004000313	A	20040325	NO 2004-313	20040123
PRIORITY APPLN. INFO.:			SE 2001-2616	A 20010725
			WO 2002-SE1403	W 20020719

OTHER SOURCE(S): MARPAT 138:137162

GI




AB Title compds. I [R¹ = NH₂, (un)substituted methyl; X = O, S; R² = H, halo, CN, NO₂, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R³ = W-Y-Z; W = O, SO₂-2; amino, CH₂(O), bond; Y = (CH₂)₀₋₂-T-(CH₂)₀₋₂; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc.; with specific exceptions] are prepared For instance, (1,1'-biphenyl-4-yl)acetone, cyanoacetamide, sulfur and morpholine in EtOH at 55° are reacted to give 2-Amino-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophenecarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC₅₀ < 10 μM for IKK2 kinase. I are useful for the treatment of inflammatory diseases.

IT 494773-75-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-tert-butylloxycarbonyl-3-pyrrolidinyl)oxy]phenyl]-3-thiophenecarboxamide
 494773-78-3P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpiperidin-2-yl)methoxy]phenyl]-3-thiophenecarboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)

RN 494773-75-0 HCAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)



RN 494773-78-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-2-

piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 494771-44-7P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(3,5-dimethylisoxazol-4-yl)methoxy]phenyl]-3-thiophenecarboxamide
 494771-46-9P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(4-chlorophenyl)methoxy]phenyl]-3-thiophenecarboxamide 494771-47-0P
 , 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(5-chlorothien-2-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-49-2P,
 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494771-52-7P,
 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(thiazol-4-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-55-0P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(1,2,5-thiadiazol-3-yl)methoxy]phenyl]-3-thiophenecarboxamide
 494771-58-3P 494772-20-2P, 2-[(Aminocarbonyl)amino]-5-[4-(cyclopropylmethoxy)phenyl]-3-thiophenecarboxamide 494772-21-3P,
 2-[(Aminocarbonyl)amino]-5-[3-(1,3-thiazol-4-ylmethoxy)phenyl]thiophene-3-carboxamide 494772-41-7P, 2-[(Aminocarbonyl)amino]-5-(2-benzyloxyphenyl)-3-thiophenecarboxamide 494772-42-8P,
 2-[(Aminocarbonyl)amino]-5-[2-(4-fluorophenylmethoxy)phenyl]-3-thiophenecarboxamide 494772-44-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-fluorophenyl)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-46-2P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-chlorophenyl)ethoxy]phenyl]-3-thiophenecarboxamide 494772-48-4P,
 2-[(Aminocarbonyl)amino]-5-[2-(2-phenylethoxy)phenyl]-3-thiophenecarboxamide 494772-63-3P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-64-4P, 2-[(Aminocarbonyl)amino]-5-[4-[2-((cyclopropyl)methoxy)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-68-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3-thiophenecarboxamide
 494772-70-2P, 2-[(Aminocarbonyl)amino]-5-[4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3-thiophenecarboxamide 494772-74-6P,
 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]-3-thiophenecarboxamide 494772-76-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-82-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4,4-difluoropiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-84-8P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide
 494772-97-3P, 2-[(Aminocarbonyl)amino]-5-[3-(morpholin-4-ylmethyl)-4-isobutoxyphenyl]thiophene-3-carboxamide 494773-41-0P,
 2-[(Aminocarbonyl)amino]-5-[4-(cyclopentyloxy)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-46-5P,
 2-[(Aminocarbonyl)amino]-5-[2-[2-(piperidin-1-yl)ethoxy]-4-(pyrrolidin-1-

yl)phenyl]thiophene-3-carboxamide 494773-50-1P,
2-[(Aminocarbonyl)amino]-5-[4-(piperidin-1-yl)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-52-3P,
2-[(Aminocarbonyl)amino]-5-[4-(morpholin-4-ylmethyl)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-55-6P,
2-[(Aminocarbonyl)amino]-5-[4-(2-methoxyethoxy)-2-(2-(piperidin-1-yl)ethoxy)phenyl]thiophene-3-carboxamide 494773-57-8P
494773-59-0P, 2-[(Aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]thiophene-3-carboxamide 494773-61-4P,
(R)-2-[(Aminocarbonyl)amino]-5-[2-((tetrahydrofuran-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-62-5P 494773-64-7P,
2-[(Aminocarbonyl)amino]-5-[2-((tetrahydropyran-4-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-66-9P, 2-[(Aminocarbonyl)amino]-5-[2-(cyclopropylmethoxy)phenyl]-3-thiophenecarboxamide 494773-68-1P,
2-[(Aminocarbonyl)amino]-5-[2-(cyclopentylloxy)phenyl]-3-thiophenecarboxamide 494773-70-5P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-73-8P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-ethylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-77-2P,
2-[(Aminocarbonyl)amino]-5-[2-[(pyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-80-7P, (S)-2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpyrrolidin-2-yl)methoxy]phenyl]-3-thiophenecarboxamide 494773-82-9P, 2-[(Aminocarbonyl)amino]-5-[2-[[1-(2-methoxyethyl)pyrrolidin-3-yl]oxy]phenyl]-3-thiophenecarboxamide 494773-84-1P, (R)-2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpyrrolidin-2-yl)methoxy]phenyl]-3-thiophenecarboxamide 494773-87-4P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(2,2,6-trimethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494773-90-9P, 2-[(Aminocarbonyl)amino]-5-[5-chloro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-92-1P, 2-[(Aminocarbonyl)amino]-5-[4-fluoro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-94-3P, 2-[(Aminocarbonyl)amino]-5-[4,5-difluoro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-96-5P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-methylphenyl]-3-thiophenecarboxamide 494773-98-7P 494774-00-4P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-methoxyphenyl]-3-thiophenecarboxamide 494774-02-6P, 2-[(Aminocarbonyl)amino]-5-[3,5-difluoro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-04-8P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-3-methoxyphenyl]-3-thiophenecarboxamide 494774-06-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-trifluoromethylphenyl]-3-thiophenecarboxamide 494774-08-2P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-4-(trifluoromethyl)phenyl]-3-thiophenecarboxamide 494774-10-6P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-4-methoxyphenyl]-3-thiophenecarboxamide 494774-12-8P, 2-[(Aminocarbonyl)amino]-5-[5-fluoro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-14-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-3-[(morpholin-4-yl)methyl]phenyl]-3-thiophenecarboxamide 494774-16-2P, 2-[(Aminocarbonyl)amino]-5-[2-[[1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy]phenyl]-3-thiophenecarboxamide 494774-18-4P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-cyclopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-21-9P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-fluoropiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-23-1P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpiperidin-4-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-25-3P, 2-[(Aminocarbonyl)amino]-5-[2-


((1-methylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide
 494774-28-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-30-0P,
 2-[(Aminocarbonyl)amino]-5-[2-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-32-2P
 494774-34-4P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(2,5-dimethyl-3-pyrrolin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)


RN 494771-44-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-46-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4-chlorophenyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-47-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(5-chloro-2-thienyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-49-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494771-52-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494771-55-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1,2,5-thiadiazol-3-ylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494771-58-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(hexahydro-1-methyl-1H-azepin-3-yl)oxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494772-20-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-21-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-41-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-42-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(4-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-44-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-fluorophenyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-46-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-chlorophenyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-48-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-phenylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-63-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-64-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(cyclopropylmethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-68-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-70-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-74-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 494772-76-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-82-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4,4-difluoro-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-84-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(3,3-difluoro-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-97-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-methylpropoxy)-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-41-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(cyclopentyloxy)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-46-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(1-piperidinyl)ethoxy]-4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 494773-50-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-piperidinylethoxy)-2-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

(1-piperidinyl)ethoxy]phenyl] - (9CI) (CA INDEX NAME)




RN 494773-52-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinylmethyl)-2-[2-(1-piperidinyl)ethoxy]phenyl] - (9CI) (CA INDEX NAME)




RN 494773-55-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-methoxyethoxy)-2-[2-(1-piperidinyl)ethoxy]phenyl] - (9CI) (CA INDEX NAME)




RN 494773-57-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinyl)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-59-0 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-(2-hydroxyethoxy)phenyl)]- (9CI) (CA INDEX NAME)



RN 494773-61-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(3R)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 494773-62-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(3S)-tetrahydro-3-furanyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-64-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-66-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-68-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(cyclopentyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-70-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-73-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-77-2 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(3-pyrrolidinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 494773-80-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 494773-82-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(2-methoxyethyl)-2-methylpyrrolidin-1-yl]methoxy]phenyl]- (9CI) (CA INDEX NAME)


3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-84-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-87-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,2,6-trimethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-90-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-chloro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-92-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-fluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-94-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4,5-difluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-96-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-methyl-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-98-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-cyano-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-00-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-02-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3,5-difluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-04-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-06-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-08-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-10-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-12-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-fluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-14-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-16-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(cyclopropylmethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-18-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-cyclopropyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-21-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(4-fluoro-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-23-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-4-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-25-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-28-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-hydroxy-1-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-30-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,2,6,6-tetramethyl-1-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-32-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494774-34-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,5-dihydro-2,5-dimethyl-1H-pyrrol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:597977 HCAPLUS

DOCUMENT NUMBER: 135:180698

TITLE: Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2

INVENTOR(S): Baxter, Andrew; Brough, Stephen; Faull, Alan; Johnstone, Craig; Mcinally, Thomas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058890	A1	20010816	WO 2001-SE248	20010207
W. AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396824	AA	20010816	CA 2001-2396824	20010207
EP 1261600	A1	20021204	EP 2001-902951	20010207
EP 1261600	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008143	A	20030121	BR 2001-8143	20010207
JP 2003522766	T2	20030729	JP 2001-558440	20010207
AT 266019	E	20040515	AT 2001-902951	20010207
NZ 519947	A	20040528	NZ 2001-519947	20010207
PT 1261600	T	20040831	PT 2001-902951	20010207
ES 2218376	T3	20041116	ES 2001-1902951	20010207
AU 781047	B2	20050505	AU 2001-30705	20010207
US 2002107252	A1	20020808	US 2002-868884	20020205
ZA 2002005300	A	20031002	ZA 2002-5300	20020702
NO 2002003786	A	20020923	NO 2002-3786	20020809

PRIORITY APPLN. INFO.:

GB 2000-3154

A 20000212


WO 2001-SE248

W 20010207


OTHER SOURCE(S):

MARPAT 135:180698

GI



I



II

AB The title compds. [I; A = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared. Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH2Cl2 afforded II.


IT 354811-31-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-31-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




IT 354811-34-0P 354811-35-1P 354811-38-4P
 354811-39-5P 354811-40-8P 354811-42-0P
 354811-50-0P 354811-51-1P 354811-52-2P
 354811-66-8P 354811-79-3P 354811-80-6P
 354811-81-7P 354811-82-8P 354811-83-9P
 354811-84-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)


RN 354811-34-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-35-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-38-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-39-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-40-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-42-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 354811-50-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-51-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-52-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-66-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 354811-79-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-80-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-81-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 354811-82-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-83-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-84-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 354812-11-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354812-11-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 , THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l10 ibib abs hitstr tot

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:606462 HCAPLUS

DOCUMENT NUMBER: 141:157027

TITLE: Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.

INVENTOR(S): Faull, Alan Wellington; Johnstone, Craig; Morley, Andrew David; Poyser, Jeffrey Philip

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063186	A1	20040729	WO 2004-GB96	20040113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ			
EP 1583755	A1	20051012	EP 2004-701627	20040113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006516273	T2	20060629	JP 2006-500200	20040113
US 2006058522	A1	20060316	US 2005-542326	20050713 <--
PRIORITY APPLN. INFO.:			SE 2003-92	A 20030115
			WO 2004-GB96	W 20040113
OTHER SOURCE(S):	MARPAT 141:157027			
GI				



AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; R3, R4 = H, CH3; A = 6-membered aromatic ring optionally incorporating one or two nitrogen atoms; X = NR6; R5 = H, Cl, alkyl, etc.; R6 = H, Cl, alkyl] and their pharmaceutically acceptable salts were prepared. For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 4-bromobenzylbromide and 2,2,2-trifluoroethylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.00056-0.066 μ M, e.g., the IC50 value of thiophenylcarboxamide III was 0.0036 μ M. Compds. I are claimed useful for the treatment of inflammatory diseases.


IT 728947-61-3P 728947-62-4P 728947-63-5P
 728947-64-6P 728947-65-7P 728947-66-8P
 728947-67-9P 728947-68-0P 728947-69-1P
 728947-70-4P 728947-71-5P 728947-72-6P
 728947-73-7P 728947-74-8P 728947-75-9P
 728947-76-0P 728947-77-1P 728947-78-2P
 728947-79-3P 728947-80-6P 728947-81-7P
 728947-82-8P 728947-83-9P 728947-84-0P
 728947-85-1P 728947-86-2P 728947-87-3P
 728947-88-4P 728947-89-5P 728947-90-8P
 728947-91-9P 728947-93-1P 728947-94-2P
 728947-95-3P 728947-97-5P 728947-98-6P
 728948-18-3P 728948-19-4P 728948-20-7P
 728948-21-8P 728948-22-9P 728948-23-0P
 728948-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)


RN 728947-61-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-62-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[1-methylethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-63-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[bis(2-methoxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-64-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[ethyl(2-methoxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-65-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-66-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2-methoxyethyl)(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-67-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2-methoxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-68-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-69-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 728947-70-4 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[[[(aminocarbonyl)amino]-5-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 728947-71-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2R)-2-hydroxypropyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 728947-72-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2S)-2-hydroxypropyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 728947-73-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-74-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(4-fluorophenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-75-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-76-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[1-naphthalenylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-77-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-78-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(cyclopentylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-79-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[3-pyridinylmethyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-80-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[2-(2-pyridinyl)ethyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-81-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[2-hydroxy-1,1-dimethylethyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-82-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[1,2-diphenylethyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-83-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-methoxy-1-methylethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-84-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-hydroxy-1-methylethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-85-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[2-methylphenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-86-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(3-methoxyphenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-87-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2-fluorophenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-88-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(3-fluorophenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-89-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4-phenylbutyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-90-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[3-(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 728947-91-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[5-cyanopentyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728947-93-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[2-methylpropyl]amino]methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 728947-92-0


CMF C17 H22 N4 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 728947-94-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(4-methoxyphenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 728947-95-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-phenylethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 728947-97-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-hydroxyethyl)amino]methyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI)

(CA INDEX NAME)

CM 1

CRN 728947-96-4


CMF C15 H18 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 728947-98-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(2-methoxy-2-methylpropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-18-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3-methoxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-19-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(diethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-20-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-cyanoethyl)methylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-21-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-cyanoethyl)(phenylmethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-22-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-(hydroxyethyl)methylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-23-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-(hydroxyethyl)(phenylmethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 728948-24-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[bis(2-(hydroxyethyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)





IT 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)
 RN 494773-25-0 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (9CI)
 (CA INDEX NAME)



L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:606461 HCAPLUS
 DOCUMENT NUMBER: 141:157026
 TITLE: Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
 INVENTOR(S): Morley, Andrew David; Poyser, Jeffrey Philip
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063185	A1	20040729	WO 2004-GB106	20040113
WO 2004063185	C1	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004203967	A1	20040729	AU 2004-203967	20040113
CA 2512336	AA	20040729	CA 2004-2512336	20040113

EP 1583756 A1 20051012 EP 2004-701632 20040113
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2004006774 A 20051227 BR 2004-6774 20040113
 CN 1738812 A 20060222 CN 2004-80002304 20040113
 JP 2006515355 T2 20060525 JP 2006-500206 20040113
 US 2006111431 A1 20060525 US 2005-542044 20050713 <--
 NO 2005003810 A 20051012 NO 2005-3810 20050812
 PRIORITY APPLN. INFO.: SE 2003-91 A 20030115
 WO 2004-GB106 A 20040113
 OTHER SOURCE(S): MARPAT 141:157026
 GI



AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; X = C(R4R5)_yNR3(CR4R5)_m-Ar; y = n + 1; n = 1-3; m = 0-3; R3 = H, (un)substituted alkenyl, alkyl; R4, R5 = H, alkyl with provisos; Ar = Ph ring or a 5- or 6- membered heterocyclic ring containing one to three heteroatoms, e.g., O, N, S;] and their pharmaceutically acceptable salts were prepared For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 1-bromo-2-[2-chloroethoxy]benzene and N-methylbenzylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 6-examples of compds. I exhibited IC50 values ranging from 0.01-1.43 μM, e.g., the IC50 value of thiophenylcarboxamide III was 0.04 μM. Compds. I are claimed useful for the treatment of inflammatory diseases.


IT 727741-81-3P 727741-82-4P 727741-83-5P,
 2-[(Aminocarbonyl)amino]-5-[2-[2-(benzylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-84-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(benzyl-N-methylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-85-7P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]phenyl]thiophene-3-carboxamide 727741-86-8P, 2-[(Aminocarbonyl)amino]-5-[2-[1-(4-fluorobenzyl)pyrrolidin-3-yl]oxy]phenyl]thiophene-3-carboxamide 727741-87-9P, 2-[(Aminocarbonyl)amino]-5-[2-(1-benzylpyrrolidin-3-yloxy)phenyl]thiophene-3-carboxamide 727741-88-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-

fluorobenzyl)amino]ethoxy]phenyl]thiophene-3-carboxamide
 727741-89-1P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-3-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-90-4P
 , 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-2-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide 727741-91-5P
 , 2-[(Aminocarbonyl)amino]-5-[2-[2-(pyridin-4-ylmethylamino)ethoxy]phenyl]thiophene-3-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)


RN 727741-81-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[(2-chlorophenyl)methyl]methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-82-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[(4-chlorophenyl)methyl]methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-83-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-84-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-85-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(1,3-dihydro-2H-isoindol-2-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-86-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-[(4-fluorophenyl)methyl]-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-87-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-88-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2-[[[4-(4-fluorophenyl)methyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-89-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2-(methyl-3-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 727741-90-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 727741-91-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(methyl-4-pyridinylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 727741-95-9P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-benzylcarbamate
 727742-03-2P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-(4-fluorobenzyl)carbamate
 727742-06-5P, tert-Butyl-N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-yl]phenoxy]ethyl]-N-pyridin-3-ylmethylcarbamate
 727742-09-8P, tert-Butyl N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-


yl]phenoxy]ethyl]-N-(pyridin-2-ylmethyl)carbamate 727742-12-3P,
tert-Butyl-N-[2-[2-[3-(aminocarbonyl)-2-[(aminocarbonyl)amino]thien-5-

yl]phenoxy]ethyl]-N-pyridin-4-ylmethylcarbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment
of inflammatory diseases.)


RN 727741-95-9 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 727742-03-2 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl][(4-fluorophenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 727742-06-5 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl](3-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 727742-09-8 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl] (2-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 727742-12-3 HCAPLUS

CN Carbamic acid, [2-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]ethyl] (4-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:515662 HCAPLUS

DOCUMENT NUMBER: 141:47386

TITLE: Ureidothiophene compound NF- κ B inhibitor for therapeutic use

INVENTOR(S): Callahan, James Frances; Li, Yue Hu

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004053087	A2	20040624	WO 2003-US38970	20031205
WO 2004053087	A3	20040910		
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, VN, YU, ZA				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300832	A1	20040630	AU 2003-300832	20031205
EP 1569924	A2	20050907	EP 2003-812858	20031205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510676	T2	20060330	JP 2004-559435	20031205
US 2006116419	A1	20060601	US 2005-537697	20050606 <--
PRIORITY APPLN. INFO.:			US 2002-431496P	P 20021206
			WO 2003-US38970	W 20031205
AB	The invention provides 5-(4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide (preparation described) and methods for treating diseases related to the inhibition of IKK- β phosphorylation of Ik.			
IT	507475-17-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (ureidothiophene compound NF- κ B inhibitor for therapeutic use)			
RN	507475-17-4 HCAPLUS			
CN	3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)			



L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:97411 HCAPLUS

DOCUMENT NUMBER: 138:137162

TITLE: Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase

INVENTOR(S): Faull, Alan; Johnstone, Craig; Morley, Andrew; Poyser, Jeffrey Philip

PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.

SOURCE: PCT Int. Appl., 180 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2454703	AA	20030206	CA 2002-2454703	20020719
EP 1421074	A1	20040526	EP 2002-751935	20020719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011473	A	20041026	BR 2002-11473	20020719
CN 1541214	A	20041027	CN 2002-815836	20020719
JP 2005503372	T2	20050203	JP 2003-515517	20020719
NZ 530750	A	20050826	NZ 2002-530750	20020719
US 2004242573	A1	20041202	US 2004-484569	20040122 <--
US 7125896	B2	20061024		
ZA 2004000492	A	20050422	ZA 2004-492	20040122
NO 2004000313	A	20040325	NO 2004-313	20040123
PRIORITY APPLN. INFO.:			SE 2001-2616	A 20010725
			WO 2002-SE1403	W 20020719

OTHER SOURCE(S): MARPAT 138:137162


GI




- AB Title compds. I [R1 = NH₂, (un)substituted methyl; X = O, S; R2 = H, halo, CN, NO₂, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R3 = W-Y-Z; W = O, SO₂-2; amino, CH₂(O), bond; Y = (CH₂)₀₋₂-T-(CH₂)₀₋₂; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc.; with specific exceptions] are prepared For instance, (1,1'-biphenyl-4-yl)acetone, cyanoacetamide, sulfur and morpholine in EtOH at 55° are reacted to give 2-Amino-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophenecarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC₅₀ < 10 μM for IKK2 kinase. I are useful for the treatment of inflammatory diseases.
- IT 494773-24-9P, 2-[(Aminocarbonyl)amino]-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-33-0P, 2-[(Aminocarbonyl)amino]-5-[4-[(4-hydroxypiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-75-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-tert-butyloxycarbonyl-3-pyrrolidinyl)oxy]phenyl]-3-thiophenecarboxamide 494773-78-3P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpiperidin-2-yl)methoxy]phenyl]-3-thiophenecarboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)
- RN 494773-24-9 HCAPLUS
- CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



- RN 494773-33-0 HCAPLUS
- CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4-hydroxy-1-piperidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




- RN 494773-75-0 HCAPLUS
- CN 1-Pyrrolidinecarboxylic acid, 3-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 494773-78-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-2-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 494771-42-5P, 2-[(Aminocarbonyl)amino]-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophenecarboxamide 494771-44-7P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(3,5-dimethylisoxazol-4-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-46-9P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(4-chlorophenyl)methoxy]phenyl]-3-thiophenecarboxamide 494771-47-0P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(5-chlorothien-2-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-49-2P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494771-52-7P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(thiazol-4-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-55-0P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-[(1,2,5-thiadiazol-3-yl)methoxy]phenyl]-3-thiophenecarboxamide 494771-58-3P, 494772-19-9P, 2-[(Aminocarbonyl)amino]-5-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-thiophenecarboxamide 494772-20-2P, 2-[(Aminocarbonyl)amino]-5-[4-(cyclopropylmethoxy)phenyl]-3-thiophenecarboxamide 494772-21-3P, 2-[(Aminocarbonyl)amino]-5-[3-(1,3-thiazol-4-ylmethoxy)phenyl]thiophene-3-carboxamide 494772-23-5P, 2-[(Aminocarbonyl)amino]-5-[4-(morpholin-4-ylmethyl)phenyl]thiophene-3-carboxamide 494772-41-7P, 2-[(Aminocarbonyl)amino]-5-(2-benzyloxyphenyl)-3-thiophenecarboxamide

494772-42-8P, 2-[(Aminocarbonyl)amino]-5-[2-(4-fluorophenylmethoxy)phenyl]-3-thiophenecarboxamide 494772-44-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-fluorophenyl)ethoxy]phenyl]-3-thiophenecarboxamide 494772-46-2P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-chlorophenyl)ethoxy]phenyl]-3-thiophenecarboxamide 494772-48-4P, 2-[(Aminocarbonyl)amino]-5-[2-(2-phenylethoxy)phenyl]-3-thiophenecarboxamide 494772-52-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(morpholinyl)ethylsulfanyl]phenyl]-3-thiophenecarboxamide 494772-54-2P 494772-56-4P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(piperidinyl)ethylsulfanyl]phenyl]-3-thiophenecarboxamide 494772-58-6P, 2-[(Aminocarbonyl)amino]-5-[4-(pyrrolidinyl)phenyl]-3-thiophenecarboxamide 494772-59-7P, 2-[(Aminocarbonyl)amino]-5-[4-(piperidinyl)phenyl]-3-thiophenecarboxamide 494772-60-0P, 2-[(Aminocarbonyl)amino]-5-[4-(imidazolyl)phenyl]-3-thiophenecarboxamide 494772-63-3P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-64-4P, 2-[(Aminocarbonyl)amino]-5-[4-[2-((cyclopropyl)methoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-68-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3-thiophenecarboxamide 494772-70-2P, 2-[(Aminocarbonyl)amino]-5-[4-(tetrahydrofuran-2-ylmethoxy)phenyl]-3-thiophenecarboxamide 494772-74-6P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]-3-thiophenecarboxamide 494772-76-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-78-0P, 2-[(Aminocarbonyl)amino]-5-[2-(4-methylpiperazinylmethyl)phenyl]-3-thiophenecarboxamide 494772-80-4P, 2-[(Aminocarbonyl)amino]-5-[2-(4-isopropylpiperazinylmethyl)phenyl]-3-thiophenecarboxamide 494772-81-5P, 2-[(Aminocarbonyl)amino]-5-[4-(pyrrolidinylmethyl)phenyl]thiophene-3-carboxamide 494772-82-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4,4-difluoropiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494772-84-8P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494772-93-9P, 2-[(Aminocarbonyl)amino]-5-[4-(cis-2,6-dimethylmorpholin-4-ylmethyl)phenyl]thiophene-3-carboxamide 494772-95-1P, 2-[(Aminocarbonyl)amino]-5-[4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)methyl]phenyl]thiophene-3-carboxamide 494772-97-3P, 2-[(Aminocarbonyl)amino]-5-[3-(morpholin-4-ylmethyl)-4-isobutoxyphenyl]thiophene-3-carboxamide 494772-99-5P, 2-[(Aminocarbonyl)amino]-5-[3-(morpholin-4-ylmethyl)phenyl]thiophene-3-carboxamide 494773-00-1P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(methoxymethyl)morpholin-4-yl]methyl]phenyl]thiophene-3-carboxamide 494773-02-3P, 2-[(Aminocarbonyl)amino]-5-[3-fluoro-4-(morpholin-4-ylmethyl)phenyl]thiophene-3-carboxamide 494773-03-4P 494773-05-6P, 2-[(Aminocarbonyl)amino]-5-[4-[4-(4,4-difluoropiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-07-8P, 2-[(Aminocarbonyl)amino]-5-[4-[1-(piperidin-1-yl)ethyl]phenyl]thiophene-3-carboxamide 494773-09-0P 494773-11-4P, 2-[(Aminocarbonyl)amino]-5-[4-[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]thiophene-3-carboxamide 494773-13-6P, 2-[(Aminocarbonyl)amino]-5-[4-((piperidin-1-yl)methyl)phenyl]thiophene-3-carboxamide 494773-14-7P, 2-[(Aminocarbonyl)amino]-5-[4-[[1S,4S]-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]methyl]phenyl]thiophene-3-carboxamide 494773-16-9P, 5-[4-[4-Acetylpiperazin-1-yl)methyl]phenyl]-2-[(aminocarbonyl)amino]thiophene-3-carboxamide 494773-18-1P, 2-[(Aminocarbonyl)amino]-5-[4-(1,4-oxazepan-4-ylmethyl)phenyl]thiophene-3-carboxamide 494773-20-5P 494773-22-7P,

2-[(Aminocarbonyl)amino]-5-[4-[1-methyl-1-(morpholin-4-yl)ethyl]phenyl]thiophene-3-carboxamide 494773-26-1P,
2-[(Aminocarbonyl)amino]-5-[4-[(2-ethoxycarbonylpiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-27-2P,
2-[(Aminocarbonyl)amino]-5-[4-[(3-diethylaminocarbonylpiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-28-3P,
2-[(Aminocarbonyl)amino]-5-[4-[(3-hydroxypyrrolidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494773-29-4P
494773-30-7P, 2-[(Aminocarbonyl)amino]-4-methyl-5-[4-((morpholinyl)methyl)phenyl]-3-thiophenecarboxamide 494773-34-1P
, 2-[(Aminocarbonyl)amino]-5-(2-(piperazin-1-yl)phenyl)thiophene-3-carboxamide 494773-37-4P, 2-[(Aminocarbonyl)amino]-5-[2-(4-methylpiperazin-1-yl)phenyl]thiophene-3-carboxamide 494773-38-5P
, 2-[(Aminocarbonyl)amino]-5-[2-[3-(methylamino)pyrrolidin-1-yl]phenyl]thiophene-3-carboxamide 494773-41-0P,
2-[(Aminocarbonyl)amino]-5-[4-(cyclopentyloxy)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-46-5P,
2-[(Aminocarbonyl)amino]-5-[2-[2-(piperidin-1-yl)ethoxy]-4-(pyrrolidin-1-yl)phenyl]thiophene-3-carboxamide 494773-50-1P,
2-[(Aminocarbonyl)amino]-5-[4-(piperidin-1-yl)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-52-3P,
2-[(Aminocarbonyl)amino]-5-[4-(morpholin-4-ylmethyl)-2-[2-(piperidin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494773-55-6P,
2-[(Aminocarbonyl)amino]-5-[4-(2-methoxyethoxy)-2-(2-(piperidin-1-yl)ethoxy)phenyl]thiophene-3-carboxamide 494773-57-8P
494773-59-0P, 2-[(Aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]thiophene-3-carboxamide 494773-61-4P,
(R)-2-[(Aminocarbonyl)amino]-5-[2-((tetrahydrofuran-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-62-5P 494773-64-7P,
2-[(Aminocarbonyl)amino]-5-[2-((tetrahydropyran-4-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-66-9P, 2-[(Aminocarbonyl)amino]-5-[2-(cyclopropylmethoxy)phenyl]-3-thiophenecarboxamide 494773-68-1P,
2-[(Aminocarbonyl)amino]-5-[2-(cyclopentyloxy)phenyl]-3-thiophenecarboxamide 494773-70-5P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494773-73-8P,
2-[(Aminocarbonyl)amino]-5-[2-((1-ethylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-77-2P,
2-[(Aminocarbonyl)amino]-5-[2-((pyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-80-7P, (S)-2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpyrrolidin-2-yl)methoxy]phenyl]-3-thiophenecarboxamide 494773-82-9P,
2-[(Aminocarbonyl)amino]-5-[2-[[1-(2-methoxyethyl)pyrrolidin-3-yl]oxy]phenyl]-3-thiophenecarboxamide 494773-84-1P, (R)-2-[(Aminocarbonyl)amino]-5-[2-((1-methylpyrrolidin-2-yl)methoxy)phenyl]-3-thiophenecarboxamide 494773-87-4P,
2-[(Aminocarbonyl)amino]-5-[2-[2-(2,2,6-trimethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494773-90-9P,
2-[(Aminocarbonyl)amino]-5-[5-chloro-2-((1-isopropylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-92-1P,
2-[(Aminocarbonyl)amino]-5-[4-fluoro-2-((1-isopropylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-94-3P,
2-[(Aminocarbonyl)amino]-5-[4,5-difluoro-2-((1-isopropylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494773-96-5P,
2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-methylphenyl]-3-thiophenecarboxamide 494773-98-7P 494774-00-4P,
2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-methoxyphenyl]-3-thiophenecarboxamide 494774-02-6P,
2-[(Aminocarbonyl)amino]-5-[3,5-difluoro-2-((1-isopropylpyrrolidin-3-yl)oxy)phenyl]-3-thiophenecarboxamide 494774-04-8P,
2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-3-methoxyphenyl]-3-thiophenecarboxamide


494774-06-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-5-trifluoromethylphenyl]-3-thiophenecarboxamide 494774-08-2P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-4-(trifluoromethyl)phenyl]-3-thiophenecarboxamide 494774-10-6P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-4-methoxyphenyl]-3-thiophenecarboxamide 494774-12-8P, 2-[(Aminocarbonyl)amino]-5-[5-fluoro-2-[(1-isopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-14-0P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-isopropylpyrrolidin-3-yl)oxy]-3-[(morpholin-4-yl)methyl]phenyl]-3-thiophenecarboxamide 494774-16-2P, 2-[(Aminocarbonyl)amino]-5-[2-[[1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy]phenyl]-3-thiophenecarboxamide 494774-18-4P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-cyclopropylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-21-9P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-fluoropiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-23-1P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpiperidin-4-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-25-3P, 2-[(Aminocarbonyl)amino]-5-[2-[(1-methylpyrrolidin-3-yl)oxy]phenyl]-3-thiophenecarboxamide 494774-27-5P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(morpholin-4-yl)acetyl]phenyl]-3-thiophenecarboxamide 494774-28-6P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-30-0P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl]-3-thiophenecarboxamide 494774-32-2P 494774-34-4P, 2-[(Aminocarbonyl)amino]-5-[2-[2-(2,5-dimethyl-3-pyrrolin-1-yl)ethoxy]phenyl]thiophene-3-carboxamide 494774-36-6P, (S)-2-[(Aminocarbonyl)amino]-5-[4-(2-methoxymethylpyrrolidin-1-ylmethyl)phenyl]thiophene-3-carboxamide 494774-37-7P, 2-[(Aminocarbonyl)amino]-5-[4-[(4-aminocarbonylpiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494774-38-8P, 2-[(Aminocarbonyl)amino]-5-[4-[(3-hydroxymethylpiperidin-1-yl)methyl]phenyl]thiophene-3-carboxamide 494774-39-9P, 2-[(Aminocarbonyl)amino]-5-[4-(4-hydroxymethylpiperidin-1-ylmethyl)phenyl]thiophene-3-carboxamide 494774-40-2P, 2-[(Aminocarbonyl)amino]-5-[2-[3-(morpholin-4-yl)pyrrolidin-1-yl]phenyl]thiophene-3-carboxamide 494774-43-5P, 2-[(Aminocarbonyl)amino]-5-[2-[4-(2-methoxyethyl)piperazin-1-yl]phenyl]thiophene-3-carboxamide 494774-45-7P, 2-[(Aminocarbonyl)amino]-5-[2-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]phenyl]thiophene-3-carboxamide 494775-33-6P, 2-[(Aminocarbonyl)amino]-5-[2-[(4-(tert-butyloxycarbonyl)piperazinyl)methyl]phenyl]-3-thiophenecarboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)


RN 494771-42-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[1,1'-biphenyl]-4-yl-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-44-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-46-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4-chlorophenyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-47-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(5-chloro-2-thienyl)methoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494771-49-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494771-52-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494771-55-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1,2,5-thiadiazol-3-ylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494771-58-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(hexahydro-1-methyl-1H-azepin-3-yl)oxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 494772-19-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1,3,4-oxadiazol-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-20-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-21-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-23-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-41-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-42-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(4-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-44-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-fluorophenyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-46-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-chlorophenyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-48-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-phenylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-52-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2-(4-morpholinyl)ethyl]thio]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-54-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2-(1-pyrrolidinyl)ethyl]thio]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-56-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2-(1-piperidinyl)ethyl]thio]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-58-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-59-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-60-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-63-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-64-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(cyclopropylmethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-68-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-70-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-74-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 494772-76-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-78-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-80-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494772-81-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-82-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4,4-difluoro-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494772-84-8 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(3,3-difluoro-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494772-93-9 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2,6-dimethyl-4-morpholinyl]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 494772-95-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(8-oxa-3-azabicyclo[3.2.1]oct-3-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-97-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-methylpropoxy)-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494772-99-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-00-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[2-(methoxymethyl)-4-morpholinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-02-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-fluoro-4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-03-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-05-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(4,4-difluoro-1-piperidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-07-8 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[1-(1-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-09-0 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(1R)-1-(4-morpholinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-11-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-13-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-piperidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 494773-14-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-16-9 HCAPLUS

CN 3-Thiophenecarboxamide, 5-[4-[(4-acetyl-1-piperazinyl)methyl]phenyl]-2-[(aminocarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 494773-18-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-20-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(1S)-1-(4-morpholinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-22-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[1-methyl-1-(4-morpholinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-26-1 HCAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[4-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 494773-27-2 HCAPLUS

CN 3-Piperidinecarboxamide, 1-[[4-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 494773-28-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(3-hydroxy-1-pyrrolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-29-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-30-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-34-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-37-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-38-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-41-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(cyclopentyloxy)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI). (CA INDEX NAME)




RN 494773-46-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(1-piperidinyl)ethoxy]-4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-50-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(1-piperidinyl)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-52-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinylmethyl)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-55-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(2-methoxyethoxy)-2-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-57-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinyl)-2-[2-(1-piperidinyloxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-59-0 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-(2-hydroxyethoxy)phenyl)- (9CI) (CA INDEX NAME)



RN 494773-61-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(3R)-tetrahydro-3-furanyloxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 494773-62-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(3S)-tetrahydro-3-furanyloxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-64-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-66-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-68-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(cyclopentyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494773-70-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-73-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-77-2 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(3-pyrrolidinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 494773-80-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[2S]-1-methyl-2-pyrrolidinyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 494773-82-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(2-methoxyethyl)-


3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494773-84-1 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494773-87-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,2,6-trimethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-90-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-chloro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-92-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-fluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-94-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4,5-difluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-96-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-methyl-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494773-98-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-cyano-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-00-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-02-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3,5-difluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-04-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-06-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-08-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-10-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-methoxy-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-12-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[5-fluoro-2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-14-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]-3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-16-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[[1-(cyclopropylmethyl)-3-pyrrolidinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-18-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-cyclopropyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-21-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-fluoro-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-23-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-4-piperidinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-25-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-27-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-morpholinylacetyl)phenyl]- (9CI) (CA INDEX NAME)




RN 494774-28-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-30-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-32-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494774-34-4 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-(2,5-dihydro-2,5-dimethyl-1H-pyrrol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 494774-36-6 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494774-37-7 HCAPLUS

CN 4-Piperidinecarboxamide, 1-[[[4-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 494774-38-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[3-(hydroxymethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-39-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[4-(hydroxymethyl)-1-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 494774-40-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[3-(4-morpholinyl)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494774-43-5 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 494774-45-7 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-ylphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 494775-33-6 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-thienyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 494772-79-1P, 2-[(Aminocarbonyl)amino]-5-(2-formylphenyl)-3-thiophenecarboxamide 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide 494773-36-3P, 2-[(Aminocarbonyl)amino]-5-[2-(4-tert-butyloxycarbonylpiperazin-1-yl)phenyl]thiophene-3-carboxamide 494773-40-9P, 2-[(Aminocarbonyl)amino]-5-[2-[3-(N-tert-butyloxycarbonyl-N-methylamino)pyrrolidin-1-yl]phenyl]thiophene-3-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)
 RN 494772-79-1 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-formylphenyl)- (9CI)
 (CA INDEX NAME)




RN 494773-25-0 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (9CI)
 (CA INDEX NAME)




RN 494773-36-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[4-(aminocarbonyl)-5-
[(aminocarbonyl)amino]-2-thienyl]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 494773-40-9 HCAPLUS

CN Carbamic acid, [1-[2-[4-(aminocarbonyl)-5-[(aminocarbonyl)amino]-2-
thienyl]phenyl]-3-pyrrolidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:293385 HCAPLUS

DOCUMENT NUMBER: 136:325411

TITLE: Preparation of 2-aminothiophene-3-carboxamides as
NF-κB inhibitors

INVENTOR(S): Callahan, James F.; Roshak, Amy K.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND

DATE

APPLICATION NO.


DATE

```

-----
WO 2002030353      A2      20020418      WO 2001-US31866      20011012
WO 2002030353      A3      20020627
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
    PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
    US, UZ, VN, YU, ZA, ZW
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
    DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
    BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002011663      A5      20020422      AU 2002-11663      20011012
EP 1324759         A2      20030709      EP 2001-979731      20011012
R:   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523476      T2      20040805      JP 2002-533800      20011012
US 2004024047      A1      20040205      US 2003-398847      20030410 <--
US 2006030596      A1      20060209      US 2005-237232      20050928 <--
PRIORITY APPLN. INFO.:
                                US 2000-239759P      P 20001012
                                WO 2001-US31866      W 20011012
                                US 2003-398847      B1 20030410

OTHER SOURCE(S):      MARPAT 136:325411
GI


```



AB The title compds. [I; R1 = NR5R6; R2 = CONH2, SO2NH2; R3 = H, halo; R4 = aryl, heteroaryl; R5 = H, alkyl; R6 = H, COalkyl, SO2alkyl, etc.], useful as inhibitors of IKK- β phosphorylation of I κ B, were prepared
Thus, treating (4-fluorophenyl)ethanol with PCC in CH₂Cl₂ followed by reacting the resulting (4-fluorophenyl)acetaldehyde with sulfur and 2-cyanoacetamide in the presence of Et₃N in DMF afforded 2-amino-5-(4-fluorophenyl)thiophene-3-carboxamide.


IT 106666-34-6P 106666-36-8P 412914-36-4P
412914-37-5P 412914-52-4P 412914-54-6P
412914-57-9P 412914-58-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminothiophene-3-carboxamides as NF- κ B inhibitors)

RN 106666-34-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(methylamino)carbonyl]amino]-5-phenyl]- (9CI)
(CA INDEX NAME)




RN 106666-36-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl-
(9CI) (CA INDEX NAME)




RN 412914-36-4 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[[[(methylamino)carbonyl]amino]
]- (9CI) (CA INDEX NAME)




RN 412914-37-5 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[[[(methylamino)carbonyl]amino]
]- (9CI) (CA INDEX NAME)




RN 412914-52-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(ethylamino) carbonyl] amino] -5-phenyl- (9CI)
(CA INDEX NAME)


RN 412914-54-6 HCAPLUS

CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[[(methylamino) carbonyl] amino]- (9CI) (CA INDEX NAME)




RN 412914-57-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[[(methylamino) carbonyl] amino] -5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 412914-58-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl) amino] -5-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:597977 HCAPLUS

DOCUMENT NUMBER: 135:180698

TITLE: Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2

INVENTOR(S): Baxter, Andrew; Brough, Stephen; Faull, Alan; Johnstone, Craig; Mcinally, Thomas

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058890	A1	20010816	WO 2001-SE248	20010207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396824	AA	20010816	CA 2001-2396824	20010207
EP 1261600	A1	20021204	EP 2001-902951	20010207
EP 1261600	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008143	A	20030121	BR 2001-8143	20010207
JP 2003522766	T2	20030729	JP 2001-558440	20010207
AT 266019	E	20040515	AT 2001-902951	20010207
NZ 519947	A	20040528	NZ 2001-519947	20010207
PT 1261600	T	20040831	PT 2001-902951	20010207
ES 2218376	T3	20041116	ES 2001-1902951	20010207
AU 781047	B2	20050505	AU 2001-30705	20010207
US 2002107252	A1	20020808	US 2002-868884	20020205 <--
ZA 2002005300	A	20031002	ZA 2002-5300	20020702
NO 2002003786	A	20020923	NO 2002-3786	20020809
PRIORITY APPLN. INFO.:			GB 2000-3154	A 20000212
			WO 2001-SE248	W 20010207
OTHER SOURCE(S):	MARPAT 135:180698			
GI				



AB The title compds. [I; A = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared. Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH₂Cl₂ afforded II.


IT 354811-31-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-31-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)



103


IT 354811-10-2P 354811-28-2P 354811-29-3P
 354811-30-6P 354811-32-8P 354811-33-9P
 354811-34-0P 354811-35-1P 354811-36-2P
 354811-37-3P 354811-38-4P 354811-39-5P
 354811-40-8P 354811-41-9P 354811-42-0P
 354811-48-6P 354811-49-7P 354811-50-0P
 354811-51-1P 354811-52-2P 354811-54-4P
 354811-56-6P 354811-58-8P 354811-59-9P
 354811-60-2P 354811-66-8P 354811-67-9P
 354811-68-0P 354811-79-3P 354811-80-6P
 354811-81-7P 354811-82-8P 354811-83-9P
 354811-84-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-10-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (9CI) (CA INDEX NAME)

IT 354812-11-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)
RN 354812-11-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
79.08	414.49


FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-9.75	-9.75


CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:12:58 ON 14 DEC 2006




RN 354811-28-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-29-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 354811-30-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 354811-32-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-33-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-34-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-35-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-36-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-37-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 354811-38-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-39-5 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-40-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-41-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 354811-42-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 354811-48-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-49-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-50-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-51-1 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-52-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 354811-54-4 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354811-56-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 354811-58-8 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 354811-59-9 HCAPLUS


CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10568380.trn




RN 354811-60-2 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)-
(9CI) (CA INDEX NAME)




RN 354811-66-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 354811-67-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-
(9CI) (CA INDEX NAME)




RN 354811-68-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 354811-79-3 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-80-6 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2,2,6,6-tetramethyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 354811-81-7 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(4-thiazolylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 354811-82-8 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-83-9 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 354811-84-0 HCAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

